| Description |
Recombinant Human LRIG1 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Ala35-Ser779. |
| Purity |
> 95% as determined by Tris-Bis PAGE |
| Accession |
Q96JA1 |
| Target Symbol |
LRIG1 |
| Synonyms |
LIG-1; LIG1; LRIG1; D6Bwg0781e; Img |
| Species |
Human |
| Expression System |
HEK293 |
| Tag |
C-His |
| Expression Range |
Ala35-Ser779 |
| Mol. Weight |
The protein has a predicted MW of 83 kDa. Due to glycosylation, the protein migrates to 85-105 kDa based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22um filtered solution in 50mM MES, 150mM NaCl, 1mM EDTA (pH 5.0). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Activity |
Immobilized Human LRIG1, His Tag at 2ug/ml (100ul/well) on the plate. Dose response curve for Anti-LRIG1 Antibody, hFc Tag with the EC50 of 2.9ng/ml determined by ELISA. Contact us for detailed testing images. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
The leucine-rich repeats and immunoglobulin-like domains (LRIG)-1 is a tumor suppressor gene that belongs to the LRIG family. LRIG1 expression has prognostic significance in various human cancers. Somatic mutations, which are associated with a certain rate of response to targeted therapies, are ubiquitously found in human non-small cell lung cancer (NSCLC). LRIG1 was an independent prognostic factor for OS of NSCLC patients. LRIG1 in combination with other clinicopathological risk factors was a stronger prognostic model than clinicopathological risk factors alone. |
